Abstract：
METHODS: Patients diagnosed with COVID-19 associated mucormycosis were followed up for 6 months to study the clinical profile, readmissions, long-term treatment outcome and the mortality rate.
RESULTS: Among 37 patients with COVID-19 associated mucormycosis, the mortality rate was 33.3 %, 42.9% and 100 % among patients with mild, moderate and severe COVID-19 infection. One month after discharge, among the 20 patients who survived, 10 (50 %) patients had worsening symptoms and required readmission. Nine patients required readmission for amphotericin and 1 patient was admitted for surgical intervention. On follow-up at 1 month, 30 % (6/20) patients became asymptomatic. However, at 3 months, 45 % (9/20) of the patients were asymptomatic. At 6 months of follow-up, 80 % (16/20) were asymptomatic. At 6 months, one each had residual abnormalities like visual loss in one eye, visual field deficit, change in voice and residual weakness of the limbs along with cranial nerve paresis.
CONCLUSIONS: The follow-up study revealed that a significant number of patients required readmission within the first month, but most of the patients became asymptomatic by 6 months. The readmission rate was higher in patients who received a shorter duration of amphotericin.
RESULTS: Among 37 patients with COVID-19 associated mucormycosis, the mortality rate was 33.3 %, 42.9% and 100 % among patients with mild, moderate and severe COVID-19 infection. One month after discharge, among the 20 patients who survived, 10 (50 %) patients had worsening symptoms and required readmission. Nine patients required readmission for amphotericin and 1 patient was admitted for surgical intervention. On follow-up at 1 month, 30 % (6/20) patients became asymptomatic. However, at 3 months, 45 % (9/20) of the patients were asymptomatic. At 6 months of follow-up, 80 % (16/20) were asymptomatic. At 6 months, one each had residual abnormalities like visual loss in one eye, visual field deficit, change in voice and residual weakness of the limbs along with cranial nerve paresis.
CONCLUSIONS: The follow-up study revealed that a significant number of patients required readmission within the first month, but most of the patients became asymptomatic by 6 months. The readmission rate was higher in patients who received a shorter duration of amphotericin.
摘要：
方法：对确诊为COVID-19相关性毛霉菌病的患者进行6个月的随访，以研究其临床情况。再入院,长期治疗结果和死亡率。
结果：在37例COVID-19相关性毛霉菌病患者中，死亡率为33.3%,轻度患者中的42.9%和100%，中度和重度COVID-19感染。出院后一个月，在幸存的20名患者中，10例（50％）患者症状恶化，需要再次入院。9例患者需要再次接受两性霉素治疗，1例患者接受手术干预。在1个月的随访中，30%(6/20)的患者无症状。然而,3个月时,45%(9/20)的患者无症状。随访6个月时，80%(16/20)无症状。6个月时,每个人都有一只眼睛的残余异常，例如视力丧失，视野缺损,声音和四肢残余无力的变化以及颅神经麻痹。
结论：随访研究显示，相当数量的患者在第一个月内需要再次入院，但大多数患者在6个月后无症状.接受两性霉素治疗时间较短的患者的再入院率较高。
结果：在37例COVID-19相关性毛霉菌病患者中，死亡率为33.3%,轻度患者中的42.9%和100%，中度和重度COVID-19感染。出院后一个月，在幸存的20名患者中，10例（50％）患者症状恶化，需要再次入院。9例患者需要再次接受两性霉素治疗，1例患者接受手术干预。在1个月的随访中，30%(6/20)的患者无症状。然而,3个月时,45%(9/20)的患者无症状。随访6个月时，80%(16/20)无症状。6个月时,每个人都有一只眼睛的残余异常，例如视力丧失，视野缺损,声音和四肢残余无力的变化以及颅神经麻痹。
结论：随访研究显示，相当数量的患者在第一个月内需要再次入院，但大多数患者在6个月后无症状.接受两性霉素治疗时间较短的患者的再入院率较高。
